NL8701631A - Werkwijzen voor het bereiden van een farmaceutisch preparaat en voor het behandelen van bepaalde ziekten daarmede. - Google Patents

Werkwijzen voor het bereiden van een farmaceutisch preparaat en voor het behandelen van bepaalde ziekten daarmede. Download PDF

Info

Publication number
NL8701631A
NL8701631A NL8701631A NL8701631A NL8701631A NL 8701631 A NL8701631 A NL 8701631A NL 8701631 A NL8701631 A NL 8701631A NL 8701631 A NL8701631 A NL 8701631A NL 8701631 A NL8701631 A NL 8701631A
Authority
NL
Netherlands
Prior art keywords
bromocriptine
disease
autoimmune
treatment
glomerulonephritis
Prior art date
Application number
NL8701631A
Other languages
English (en)
Dutch (nl)
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of NL8701631A publication Critical patent/NL8701631A/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NL8701631A 1986-07-14 1987-07-10 Werkwijzen voor het bereiden van een farmaceutisch preparaat en voor het behandelen van bepaalde ziekten daarmede. NL8701631A (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88511086A 1986-07-14 1986-07-14
US88511086 1986-07-14

Publications (1)

Publication Number Publication Date
NL8701631A true NL8701631A (nl) 1988-02-01

Family

ID=25386156

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8701631A NL8701631A (nl) 1986-07-14 1987-07-10 Werkwijzen voor het bereiden van een farmaceutisch preparaat en voor het behandelen van bepaalde ziekten daarmede.

Country Status (13)

Country Link
JP (1) JPS6323817A (fr)
KR (1) KR880001292A (fr)
AU (1) AU602154B2 (fr)
CH (1) CH672987A5 (fr)
DE (1) DE3722383A1 (fr)
DK (1) DK363887A (fr)
FR (1) FR2601245A1 (fr)
GB (1) GB2192541B (fr)
IT (1) IT1224222B (fr)
NL (1) NL8701631A (fr)
PH (1) PH24525A (fr)
SE (1) SE8702843L (fr)
ZA (1) ZA875145B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3814521A1 (de) * 1987-05-07 1988-11-17 Sandoz Ag Neue anwendung von dopaminrezeptor-agonisten
EP0327040A3 (fr) * 1988-02-05 1990-11-28 Predrag Dr.Sc. Sikiric Utilisation de la dopamine et/ou d'agonistes dopaminergiques pour la préparation de médicaments pour le traitement du tractus digestif
US6004972A (en) * 1988-05-10 1999-12-21 The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes
US5668155A (en) * 1988-05-10 1997-09-16 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
US5585347A (en) * 1988-05-10 1996-12-17 Ergo Science Incorporated Methods for the determination and adjustment of prolactin daily rhythms
US5716933A (en) * 1988-05-10 1998-02-10 Louisiana State University And Agricultural And Mechanical College Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
US5700800A (en) * 1988-05-10 1997-12-23 Ergo Science Incorporated Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound
US5830895A (en) * 1988-05-10 1998-11-03 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for the determination and adjustment of prolactin daily rhythms
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5744477A (en) * 1988-05-10 1998-04-28 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for treatment of obesity using prolactin modulators and diet
CA2030174C (fr) * 1990-01-10 1996-12-24 Anthony H. Cincotta Procede pour la reduction a long terme des reserves lipidiques, de l'insulinoresistance, de l'hyperinsulinemie et de l'hypoglycemie chez les vertebres
RU2104698C1 (ru) * 1991-12-23 1998-02-20 Дзе Борд оф Сьюпервайзорз оф Луизиана Стейт Юниверсити энд Эгрикалчурал энд Мекэникал Колледж Способ лечения патологических отклонений при диабете типа ii
US5696128A (en) * 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
IL112106A0 (en) * 1993-12-22 1995-03-15 Ergo Science Inc Accelerated release composition containing bromocriptine
US5714519A (en) * 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
US5626860A (en) * 1995-06-07 1997-05-06 The Board Of Supervisors Of Louisana State And Agricultural And Mechanical College Method for regulating metabolism with dopamine beta hydroxylase inhibitors
US20010016582A1 (en) 1997-04-28 2001-08-23 Anthony H. Cincotta Method and composition for the treatment of lipid and glucose metabolism disorders
ES2425581T3 (es) 2006-11-23 2013-10-16 Sinoxa Pharma Gmbh Composiciones farmacéuticas para el tratamiento de la arteriopatía capilar
EP3925610A1 (fr) * 2016-04-20 2021-12-22 VeroScience LLC Composition et procédé de traitement de troubles métaboliques
EP3697418A4 (fr) 2017-10-18 2021-07-14 VeroScience LLC Formulations de bromocriptine améliorées

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH507249A (de) * 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
GB2154874B (en) * 1984-02-29 1987-11-04 Sandoz Ltd Bromoscriptine compositions
CH666406A5 (de) * 1984-02-29 1988-07-29 Sandoz Ag Verfahren zur herstellung von mikrokapseln, welche bromokriptinmesylat als pharmakologischen wirkstoff enthalten.

Also Published As

Publication number Publication date
GB2192541B (en) 1990-05-02
FR2601245A1 (fr) 1988-01-15
SE8702843L (sv) 1988-01-15
KR880001292A (ko) 1988-04-22
DK363887D0 (da) 1987-07-13
JPS6323817A (ja) 1988-02-01
IT8748160A0 (it) 1987-07-10
DK363887A (da) 1988-01-15
SE8702843D0 (sv) 1987-07-13
GB8716323D0 (en) 1987-08-19
GB2192541A (en) 1988-01-20
IT1224222B (it) 1990-09-26
CH672987A5 (fr) 1990-01-31
AU602154B2 (en) 1990-10-04
AU7558787A (en) 1988-01-21
DE3722383A1 (de) 1988-01-28
ZA875145B (en) 1989-02-22
PH24525A (en) 1990-07-18

Similar Documents

Publication Publication Date Title
NL8701631A (nl) Werkwijzen voor het bereiden van een farmaceutisch preparaat en voor het behandelen van bepaalde ziekten daarmede.
Unger Diabetic hyperglycemia: link to impaired glucose transport in pancreatic β cells
Walter et al. The effect of adrenergic blockade on the glucagon responses to starvation and hypoglycemia in man
Beck et al. Correlative studies of growth hormone and insulin plasma concentrations with metabolic abnormalities in acromegaly
US5422352A (en) Slimming pharmaceutical composition
PATEL et al. Changes in somatostatin concentration in pancreas and other tissues of streptozotocin diabetic rats
BOYD III et al. Endocrine function and glucose metabolism in patients with Parkinson's disease and their alteration by L-dopa
HAYMOND et al. Ketotic hypoglycemia: an amino acid substrate limited disorder
Cavagnini et al. Effects of a gamma aminobutyric acid (GABA) derivative, baclofen, on growth hormone and prolactin secretion in man
Elliott et al. An abnormal insulin in juvenile diabetes mellitus
EP0170623A2 (fr) Emploi pharmaceutique de (NVA)2-cyclosporine
CZ69596A3 (en) Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility
Benson et al. Insulin autoimmunity as a cause of hypoglycemia
Ohguni et al. Correlation of plasma free thyroxine levels with insulin sensitivity and metabolic clearance rate of insulin in patients with hyperthyroid Graves' disease
Laube et al. The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance
Giugliano et al. Impaired insulin secretion in human diabetes mellitus: the effect of naloxone-induced opiate receptor blockade
Ridolfo et al. Clinical Experiences with Carbutamide, an Orally Given Hypoglycemic Agent: Preliminary Report
Gessler et al. Effect of estrogenic substance on the blood sugar of female diabetics after the menopause
US5340806A (en) Composition containing organogermanium compound and immunity adjusting agent comprising the composition
JPH07506568A (ja) 糖尿病治療のための既存の薬剤の使用
Koup et al. A single and multiple dose pharmacokinetic and metabolism study of meclofenamate sodium
Karashima et al. Superactive somatostatin analog decreases plasma glucose and glucagon levels in diabetic rats
Calafiore et al. Preventive effects of azathioprine (AZA) on the onset of diabetes mellitus in NOD mice
STöCKMANN et al. Impairment of stimulated insulin release from the isolated perfused rat pancreas by cyclosporine pretreatment
Malmary et al. Cyclosporine A dosing-time-dependent effects on plasma creatinine and body weight in male Wistar rats treated for 3 weeks

Legal Events

Date Code Title Description
BV The patent application has lapsed